Carvedilol Reduces Elevated B-type Natriuretic Peptide in Dialyzed Patients Without Heart Failure: Cardioprotective Effect of the β-blocker
Authors:
- Koichi SatoKSKoichi Sato
- Genjiro KimuraGKGenjiro Kimura
- Ryuzo UedaRURyuzo Ueda
- Yasuaki DohiYDYasuaki Dohi
- 1 April 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 49 (4) , 191-196
Abstract
Elevated plasma B-type natriuretic peptide (BNP) predicts future cardiovascular events in dialyzed patients without heart failure. We investigated whether carvedilol reduces the elevated BNP in these patients. Asymptomatic patients on chronic hemodialysis with elevated BNP but without clinical signs of heart failure were randomly assigned to receive either carvedilol (n = 10) or nothing (control group, n = 10). BNP and malondialdehyde-low density lipoprotein (MDA-LDL) were measured, and ultrasound cardiography was performed at baseline and at 3 months. Carvedilol reduced the concentrations of BNP (551 ± 90 to 237 ± 174 ng/L, P < 0.01) and MDA-LDL (174 ± 63 to 85 ± 23 U/L, P < 0.01) and increased the velocity ratio of E to A waves of the transmitral flow (E/A: 0.59 ± 0.04 to 0.71 ± 0.05, P < 0.05), while no such alterations were observed in the control group. The reduction in BNP concentration was correlated with that in MAD-LDL and the increase in the E/A. There was a significant correlation between the increase in the E/A and the reduction in MDA-LDL concentration. Thus, carvedilol reduces the elevated BNP by improving left ventricular diastolic function in dialyzed patients without heart failure, which may be attributable to the antioxidant property of the β-blocker. Administering carvedilol may improve the prognosis in this population.Keywords
This publication has 40 references indexed in Scilit:
- Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMETAmerican Heart Journal, 2005
- Chronic kidney disease: the global challengeThe Lancet, 2005
- Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fractionThe American Journal of Cardiology, 2004
- Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathyJACC, 2003
- Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunctionJACC, 2001
- Effect of Carvedilol on Survival in Severe Chronic Heart FailureNew England Journal of Medicine, 2001
- Clinical epidemiology of cardiovascular disease in chronic renal diseaseAmerican Journal of Kidney Diseases, 1998
- Attenuation of Compensation of Endogenous Cardiac Natriuretic Peptide System in Chronic Heart FailureCirculation, 1997
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996
- Natriuretic peptide system in human heart failure.Circulation, 1993